An observational study in Cellulitis and Pseudocellulitis, sponsored by Ohio State University. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by Ohio State University · Observational
The Investigators wish to study the value of dermatologic testing assessments in differentiating between cellulitis and pseudocellulitis in the inpatient setting. The Investigators propose that by utilizing cutaneous biopsies and tissue cultures in patients that have been admitted to inpatient internal medicine teams, the investigators may be able to improve multiple measures of hospital efficiency in patients presenting with cellulitis-like symptoms, by more accurately recognizing cellulitis from pseudocellulitis. The patient will undergo encrypted digital imaging for his or her condition. This image will then be sent to the study investigators, along with basic clinical information on the skin evaluation form. The study investigators will develop a differential diagnosis and then the patient will undergo a skin biopsy. The patient will then be randomized to one of two arms using a random number generator: A) Skin biopsies and tissue cultures recorded and published in patient's medical chart as they would be in a standard of care procedure B) Skin biopsies and tissue cultures consultation performed but not published in the patient's medical chart unless medically necessary. Information will be collected from medical records in IHIS. Patients will be contacted by phone 30 days after discharge.
160 studies on the registry are indexed under Cellulitis; 14 are open to participants now.
This study's enrollment of 56 is below the median of 208 across 29 observational studies indexed under Cellulitis.
Browse Cellulitis studies →Ohio State University is the lead sponsor of 663 studies on the registry; 148 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patient's ages 18 to 99 years that present in the ED with pseudocellulitis or cellulitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
The feasibility of conducting a larger study will be conducted, by establishing patient enrollment rates
According to the NIH: The goal of pilot work is not to test hypotheses about the effects of an intervention, but rather, to assess the feasibility/acceptability of an approach to be used in a larger scale study. We will use descriptive statistics to monitor patient enrollment and pilot data on additional secondary outcomes for inferential statistics.
Time frame: At study completion, around 2 years after study start
Change in antibiotic use (antibiotics/day administered) over the course of the hospitalizations
Cellulitis is a common type of bacterial skin infection. Pseudocellulitis is a skin infection that is very similar to cellulitis and is often misdiagnosed as cellulitis
Time frame: 1 year
The rate of participant readmission within 30 days
The investigators will examine 30 day readmission rates between standard care and interventional care
Time frame: 1 year
Length of hospitalization as measured in days
The investigators will examine hospital length-of-stay in patients randomized to interventional vs standard care
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2018 to primary completion in Jun 2024, 72 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.